Women’s Cancer Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute Increases Trial Participation And Decreases Costs With DocuSign


Company’s Top Objectives

Cedars-Sinai is the largest academic medical center in the western United States, with nearly 11,000 employees including 2,000 physicians across nearly every specialty. The Los Angeles-based hospital is devoted to training the next generation of healthcare professionals and is renowned for providing the highest quality patient care.

Healthcare professionals at Cedars-Sinai believe in continuously innovating and improving in order to provide the most effective treatment and services. Thus, a vital piece of Cedars-Sinai’s work is to initiate trials and studies that advance patient treatment and quality of care. DocuSign has played a significant role in the Cedars-Sinai Women’s Cancer Program (WCP), the hospital’s research center focused on developing new methods of early detection, prevention and treatments that will improve survival and quality of life for women. DocuSign has helped the Cedars-Sinai Women’s Cancer Program automate consent forms for its Research for Her Registry, Gynecologic and Breast Tissue Bank, the Gilda Radner Hereditary Cancer Program and a new study focused on the cognitive impact of surgical menopause.

Top Benefits Achieved

- Registry enrollment increased nearly 5x, from 5.4 people per month to 26.3 people per month
- 75% reduction in Turnaround Time (TAT)
- Up to $17.16 benefit per Research for Her Consent Form and up to 63% productivity gain
- $46.76 benefit per Tissue Bank, Gilda Radner Hereditary Cancer Program, and Cognitive Function Study Consent Form and up to 67% productivity gain
- Award for Best Practices in Human Subjects Protection with DocuSign
We were able to win an award for Best Practices in Human Subjects Protection from the Health Improvement Institute because of DocuSign’s help in eliminating paper-based consent forms while adhering to federal requirements and keeping participants safe. This user-friendly consent process has allowed our program to recruit more participants, further enhancing our research efforts.

Dr. BJ Rimel,
Gynecologic Oncologist and Associate Director of Gynecologic Clinical Trials,
Cedars-Sinai Women’s Cancer Program
A strenuous consent process made joining the registry easy and hassle-free.

The number of participants who elect to participate in clinical trials after joining the registry has been increasing while the cost per linkage to clinical studies continues to decrease. After integrating DocuSign into its consent agreement process, the Cedars-Sinai Women’s Cancer Program saw a 75% reduction in turnaround time (TAT) and up to 63% in productivity gain. DocuSign has been able to help Cedars-Sinai increase efficiency and improve the participants’ experience. They have also realized up to $17.16 per document savings, paying immediate returns on the hospital’s investment. The hospital’s innovation and achievements have been applauded by the Health Improvement Institute, who presented Cedars-Sinai with the 2013 Award for Excellence for their user-friendly electronic consent form.

With the Cedars-Sinai Women’s Cancer Program’s initial success in the Research for Her online registry, the medical center is expanding its use of DocuSign’s technology to other areas of the organization. In 2014, Cedars-Sinai started utilizing DocuSign’s digital transaction management technology for consenting patients to the gynecologic and breast tissue bank, the Gilda Radner Hereditary Cancer Program, and a new Cognitive Function Study. These studies are all crucial to the Cedars-Sinai Women’s Cancer Program as it allows for ongoing research on the causes and cures for cancers related to the female reproductive tract. In these new use cases, Cedars-Sinai can expect additional savings and productivity gains. Using DocuSign to automate these additional consent processes, Cedars-Sinai will realize a $46.67 benefit per document and up to a 67% productivity gain.

With the continued use of DocuSign to improve and automate its processes, Cedars-Sinai can continue their focus on developing treatments and bringing medical advancements from the laboratory to patients’ bedside.